Cognition Therapeutics to Present at Needham Virtual Healthcare Conference
Rhea-AI Summary
Cognition Therapeutics (Nasdaq: CGTX) announced that CEO Lisa Ricciardi will present at the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026 at 3:00 p.m. ET.
Ms. Ricciardi will provide program updates on development efforts for Alzheimer's disease and dementia with Lewy bodies (DLB). A live webcast is available via the company's Investor Relations site and an archived replay will be accessible for 90 days.
Positive
- None.
Negative
- None.
News Market Reaction – CGTX
In the Apr 7 session, CGTX declined 2.42%, reflecting a moderate negative market reaction. Argus tracked a peak move of +13.7% during that session. Argus tracked a trough of -5.8% from its starting point during tracking. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 31 | CEO shareholder letter | Positive | +17.4% | Outlined late-stage plans and strong Phase 2 data for DLB and Alzheimer’s. |
| Mar 26 | Earnings and pipeline | Neutral | -2.7% | Reported 2025 financials, cash runway to Q2 2027, and trial progress. |
| Mar 23 | Earnings call date | Neutral | +5.6% | Announced scheduling of Q4 and full-year 2025 results and webcast. |
| Mar 17 | Clinical data update | Positive | +6.5% | Presented SHIMMER Phase 2 data showing 86% slowing on NPI-12 in DLB. |
| Mar 02 | DLB program plans | Positive | -2.8% | Announced plans to advance zervimesine into a registrational DLB psychosis trial. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Positive clinical and program updates have often coincided with upside moves, while strategic or financial updates have produced mixed reactions.
Over the past month, CGTX has issued several clinically focused updates centered on zervimesine (CT1812) for Alzheimer’s and dementia with Lewy bodies. Phase 2 SHIMMER data and plans for a registrational DLB psychosis program saw positive price reactions on Mar 17 and Mar 31. Earnings and development updates on Mar 26 and general DLB advancement on Mar 2 drew modest pullbacks. Today’s conference presentation notice fits into this ongoing communication cadence but adds no new efficacy or financial data.
Key Terms
dementia with lewy bodies medical
dlb medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
PURCHASE, N.Y., April 07, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Company’s president and CEO, Lisa Ricciardi intends to present at the 25th Annual Needham Virtual Healthcare Conference on Monday, April 13th at 3:00 p.m. Eastern Time. During her presentation, Ms. Ricciardi will provide an update on progress of the Company's development programs for Alzheimer's disease and dementia with Lewy bodies (DLB).
A live webcast of Ms. Ricciardi's presentation will be available on the Investor Relations section of Cognition’s website or by visiting: https://event.summitcast.com/view/cCMfZsH5ZqrwSNTwfC9JDv/e5J4Cq2iB2foBnz4AT3UbN. An archived replay of the presentation will be available for 90 days following the event.
About Cognition Therapeutics:
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to helping millions of families seeking effective treatments for devastating neurodegenerative diseases through the development of novel, accessible therapies. The company has led pioneering research into the underlying mechanisms of degenerative nerve disorders. Our scientific approach builds on well-established biological pathways and translates across indications in which toxic oligomers drive disease progression, offering potential in dementia with Lewy bodies (DLB), Alzheimer’s disease, geographic atrophy, Parkinson’s, among others. The company’s lead candidate, zervimesine (CT1812), is an investigational once-daily oral therapy that has demonstrated promise in Phase 2 clinical trials in DLB and mild-to-moderate Alzheimer’s disease. Backed by nearly
About Zervimesine (CT1812)
Zervimesine (CT1812) is currently being studied in the Phase 2 START Study (NCT05531656) in patients with MCI and early Alzheimer’s disease. Phase 2 clinical studies have concluded in dementia with Lewy bodies (DLB), mild-to-moderate Alzheimer’s disease, and geographic atrophy secondary to dry AMD. Based on the strong efficacy signals observed in the Phase 2 SHIMMER study in DLB (NCT05225415), the size of the market and the unmet need, the company plans to advance zervimesine into a late-stage clinical trial for people with DLB psychosis. Zervimesine has been generally well tolerated in clinical studies to date.
The USAN Council has adopted zervimesine as the United States Adopted Name (USAN) for CT1812.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this press release or made during the conference, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding our product candidates, including zervimesine (CT1812), and any expected or implied benefits or results, including that initial clinical results observed with respect to zervimesine will be replicated in later trials and our clinical development plans, including statements regarding our clinical studies of zervimesine, any analyses of the results therefrom, as well as statements regarding our regulatory plans, are forward-looking statements. These statements, including statements relating to the timing and expected results of our clinical trials involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: competition; our ability to secure new (and retain existing) grant funding; our ability to grow and manage growth, maintain relationships with suppliers and retain our management and key employees; our ability to successfully advance our current and future product candidates through development activities, preclinical studies and clinical trials and costs related thereto; uncertainties inherent in the results of preliminary data, pre-clinical studies and earlier-stage clinical trials being predictive of the results of early or later-stage clinical trials; the timing, scope and likelihood of regulatory filings and approvals, including regulatory approval of our product candidates; changes in applicable laws or regulations; the possibility that we may be adversely affected by other economic, business or competitive factors, including ongoing economic uncertainty; our estimates of expenses and profitability; the evolution of the markets in which we compete; our ability to implement our strategic initiatives and continue to innovate our existing products; our ability to defend our intellectual property; the impacts of ongoing global and regional conflicts on our business, supply chain and labor force; our ability to maintain the listing of our common stock on the Nasdaq Capital Market; and the risks and uncertainties described more fully in the “Risk Factors” section of our annual and quarterly reports filed with the Securities & Exchange Commission and are available at www.sec.gov. These risks are not exhaustive and we face both known and unknown risks. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
| Contact Information: Cognition Therapeutics, Inc. info@cogrx.com | Mike Moyer (investors) LifeSci Advisors mmoyer@lifesciadvisors.com |
This press release was published by a CLEAR® Verified individual.
